BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Fulvio Mavilio, the Internationally Acknowledged Expert in Gene Therapy for Rare Diseases, is Appointed as Genethon's New Scientific Director


1/17/2012 10:35:27 AM

Evry, January 17, 2012 -- Fulvio Mavilio, PhD (aged 58), an international acknowledged expert and pioneer in gene therapy for rare diseases for more than twenty years, was appointed as the new Scientific Director of Généthon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (AFM) with donations from France's annual Telethon) on January 1st, 2012. He succeeds Philippe Moullier (Director of the INSERM 649 Viral Vectors and in vivo Gene Transfer Unit in Nantes, France), who had held the position since January 2009. Philippe Moullier remains a special advisor to the management and will continue his commitment to several of Généthon's scientific projects.

As a molecular biologist-geneticist by training, Fulvio Mavilio started to focus on hematology and thus blood diseases in the early 1980s. In the 1990s, his work gave rise to the worldwide first-in-man trial of stem cell gene therapy for the treatment of a rare immunodeficiency (ADA-SCID). His belief in the long-term value of gene therapy prompted him to co-found the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET). He also cofounded the gene therapy company GenEra S.p.A., who later merged into Molmed S.p.A. (a biotech company specializing in innovative cancer therapies) where he served as Director of R&D. He was also involved in setting up the University of Modena's Center for Regenerative Medicine.

Fulvio Mavilio commented that "Généthon is a world-famous benchmark organization that offers unique opportunities in gene therapy for rare diseases. With highly skilled, multidisciplinary research groups and Généthon BioProd (the world largest facility for product gene-based drugs), joining Généthon constitutes an extremely stimulating challenge!".

"We are delighted to welcome Fulvio to Généthon. His unique experience and international stature constitute significant assets for developing Généthon-led projects and making a success of the missions entrusted to us by Telethon donors and the AFM" added Généthon Chief Executive Frédéric Revah. "I heartily thank Philippe Moullier for his exception contribution over the last three years. Généthon will continue to work closely with him in his new role".

Key dates in Fulvio Mavilio's career

1995: publication of the results of the gene therapy trial in ADA-SCID (a rare blood disease).

1996: creation of the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET).

1997: publication of the results of the gene therapy trial for graft-versus-host disease (a severe complication of bone marrow transplantation).

2006: publication of the results of the gene therapy trial for epidermolysis bullosa (a rare skin disease). 2012 (January 1): appointed as Scientific Director of Généthon (Evry, France)

About Généthon

Created by the French Muscular Dystrophy Association (AFM), Généthon is funded almost exclusively by donations from France's annual Telethon. Its goal is to deliver innovative gene therapies to patients. After having played a pioneering role in deciphering the human genome, with over 200 scientists, physicians, engineers and regulatory affairs specialists, Généthon is one of the world's leading centers for preclinical and clinical research and development in the field of gene therapy for rare diseases. Généthon also has a biomanufacturing platform for clinical-grade vectors, that will open in Evry in 2012, the world's largest facility for pre-industrial pilot production (Généthon BioProd). www.genethon.fr

About the AFM

The French Muscular Dystrophy Association (AFM) federates patients with neuromuscular diseases (genetic diseases that kill, muscle after muscle) and their parents. Thanks in great part to donations from France's annual Telethon (€90 million in 2010), the AFM has become a major player in biomedical research into rare diseases in France and worldwide. It is currently funding 36 clinical trials on 31 different genetic diseases affecting the eyes, the blood, the brain, the immune system, the muscle... Thanks to its Généthon research lab, the AFM stands out through its unique ability to produce and test its own gene-based medicines.

More information at www.afm-telethon.fr

Press contacts:

AFM – Généthon

Anne-Sophie Midol, Stéphanie Bardon, Géraldine Broudin

Tel.: +33 169 472 828 / +33 645 159 587 / presse@afm.genethon.fr

ALIZE RP

Caroline Carmagnol – Mobile/Cellular: +33 664 189 959 / Tel.: +33 142 688 643 / caroline@alizerp.com

Anne-Sophie Cosquéric – Tel.: +33 142 688 641 – anne-sophie@alizerp.com


Read at BioSpace.com


Genethon
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->